Table 3.
Validations of the performance for the diagnosis of NASH in CHB patients by using established cutoffs.
| Test | Cut-offs | AUROC (95% CI) | Sensitivity | Specificity | PPV | NPV | LR+ | LR− |
|---|---|---|---|---|---|---|---|---|
| TAG_1 | 2.1298 | 0.774 (0.602–0.946) | 0.643 | 0.916 | 0.818 | 0.814 | 7.714 | 0.390 |
| TAG_1 | 1.355 | 0.833 (0.698–0.969) | 1 | 0.708 | 0.667 | 1 | 3.428 | 0 |
| CK-18 (M30) | 251.67 | 0.655 (0.466–0.843) | 0.643 | 0.681 | 0.562 | 0.750 | 2.020 | 0.524 |
| CK-18 (M65) | 721.52 | 0.393 (0.203–0.583) | 0.214 | 0.636 | 0.272 | 0.56 | 0.589 | 1.235 |
| ALT | 69.75 | 0.405 (0.212–0.597) | 0.285 | 0.6 | 0.285 | 0.6 | 0.714 | 1.190 |
CHB, active chronic hepatitis B; NASH, non-alcoholic steatohepatitis; TAG: triacylglycerol; CK-18, cytokeratin-18; ALT, alanine aminotransferase; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio.